The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates LPS-induced acute lung injury by maintenance of pulmonary microvascular barrier via activating the Epac1/AKT pathway

The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates LPS-induced acute lung injury by maintenance of pulmonary microvascular barrier via activating the Epac1/AKT pathway

Pulmonary microvascular endothelial cells (PMVECs) barrier dysfunction is a main pathophysiological feature of sepsis-related acute lung injury (ALI). This study aimed to investigate whether the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin could protect against LPS-induced PMVECs barrier disru...

Full description

Bibliographic Details
Main Authors: Na Zhang, Sihui Tang, Jinjin Zhang, Biwei Pei, Tingting Pang, Gengyun Sun
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Linagliptin
Acute lung injury
Microvascular endothelium
Barrier function
Epac1
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222010939

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222010939

Similar Items